FCE-28260
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | none |
Identifiers | |
| |
ChemSpider | 117369 |
Chemical and physical data | |
Formula | C28H35F3N2O2 |
Molar mass | 488.58 g/mol |
3D model (Jmol) | Interactive image |
| |
|
FCE-28260 is a steroidal 5α-reductase inhibitor which was developed for the treatment of benign prostatic hyperplasia and androgenic alopecia (pattern hair loss) in the 1990s but was never marketed.[1][2] FCE-28260 has been found to inhibit rat and human 5α-reductase with half-maximal inhibitory concentrations (IC50) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.[1]
References
- 1 2 Giudici, D.; Briatico, G.; Cominato, C.; Zaccheo, T.; Iehlè, C.; Nesi, M.; Panzeri, A.; Di Salle, E. (1996). "FCE 28260, a new 5 alpha-reductase inhibitor: In vitro and in vivo effects". The Journal of Steroid Biochemistry and Molecular Biology. 58 (3): 299–305. doi:10.1016/0960-0760(96)00040-4. PMID 8836165.
- ↑ EP 0782582, Salle Enrico Di, Marcella Nesi, Achille Panzeri, "Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide", published 1997-07-09.
This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.